卵巢癌HER-2/neu基因表达的临床意义

Clinical significance of expression of HER-2/neu pro-oncogene in ovarian carcinoma

目的:评价卵巢癌HER-2/neu表达的临床意义及对近期化疗效果的影响。方法:免疫组织化学ABC法检测49例卵巢癌HER-2/neu的表达。结果:1.卵巢癌HER-2/neu表达的阳性率为75.5％,表达阳性者的近期化疗有效率为24.3％,明显低于表达阴性者的近期化疗有效率75.0％(P<0.005)。2.HER-2/neu的表达与卵巢癌分化程度和临床分期密切相关(P<0.01,P<0.005)。3.HER-2/neu过表达的肿瘤具有远位转移的更大风险。结论:卵巢癌HER-2/neu的过表达明显影响近期化疗效果,并可能是其预后不良的肿瘤标志。

Purpose:to evaluate the clinical significance and relationship between chemotherapy and expression of HER-2/neu in ovarian carcinomas. Methods:Immunohistochemical technique ABC was used to detect HER-2/neu content in 49 cases of ovarian carcinomas. Results: 1. The expression positive rates of HER-2/neu in 49 cases of ovarian carcinomas was 75. 5%. The response rate to chemotherapy of patients with positive stainings was 24. 3% and lower than that of patients with negtive stainings (75. 0%) obviously, (P<0. 005). 2. There was high correlation between expression of HER-2/neu and degree of differentiation and clinical stages in ovarian carcinomas (P<0. 01 、P<0. 005). 3. HER-2/neu pro-oncogene overexpression would led to a risk of distanct metastasis easily. Conclusion:Overexpression of HER-2/neu affects obviously the recent results of chemotherapy in o-varian carcinomas, it might be a poorer prognostic marker of the tumor.